RE: SP17 Mar 2020 09:20
Good post on Advfn
superg117 Mar '20 - 08:39 - 873 of 874
iam
You can't call a £4 mill MC cap over-priced imo under the circs of where they are now.
Certain parts are jun k imo but the salt is gaining traction, products launched 97.5% owned.
Belluscura 19% interest. That company has some game changing kit due to launch this year, so what value for that company.
Currently as it stands £1 mill profit for TEK on a 15 PE is 18.75p on the SP. That means 5.5p equates to a 15 PE profit rate of £300k.
Just COPD costs the NHS about £10 bill per year, 30,000 deaths each year. The UK estimates 3 mill have it with about 1/3rd currently diagnosed.
1 in 8 hospital admissions in the UK is for COPD, yet it seems few know much about it.
2015 data and the problem is growing.
Worldwide estimates 250 mill sufferers 3.2 mill deaths per year. Again 2015 others suggest over 300 million.
So with Belluscura producing what looks like a transformational easily portable oxygen unit, which requires no oxygen tank, then it seems a big leap in convenience and costs for those that suffer with it.
So to me 19% of Belluscura alone with FDA approval weeks away and launch this year, is put potentially worth far more than the share price. Just my view.
Cold and flu viruses for such sufferers severely compound their illness.